Abstract
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children and systemic juvenile idiopathic arthritis (sJIA) accounts for 6–15% of the patients. It was found that there was spontaneous expression of IL-1β in patients with sJIA. Canakinumab (ACZ885, Canakinumab) is a human anti-IL-1β monoclonal antibody. Its mode of action is based on the neutralization of IL-1β signaling which may result in the suppression of inflammation process in patients with disorders of autoinflammatory origin including sJIA. In addition to its use in the treatment of CAPS (cryopyrin-associated periodic syndromes) and acute gouty arthritis flares in many countries, the drug provides significant advantages over existing competitive therapies, including monthly SC administration and favorable safety profile.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
